Protein Profiling company Nomic Bio announced it raised $42 million in Series B funding. This funding round will enable Nomic to accelerate the expansion of its commercial operations, further invest in advancing its state-of-the-art protein profiling platform, and broaden its transformative offerings to meet the growing demand.
A U.S.-based life-sciences-focused investor led the funding round and saw participation from new and existing investors, including Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures, and SR One. This financing brings the company’s total raised capital to more than $60 million.
Nomic is already transforming proteomics, empowering over 75 companies—spanning top-10 pharma, innovative biotechs, and prestigious research institutes. And together, they’ve collectively profiled more than 400,000 samples. In response to surging demand, Nomic has built industrial-scale facilities powered by its groundbreaking nELISA platform, offering customers a seamless protein profiling service with unmatched throughput and turnaround time.
KEY QUOTES:
“Proteomics has the potential to drive the next generation of therapeutics and diagnostics. Scalability and data fidelity are critical for proteomics technologies. But for broad adoption and utility, the technology must also be broadly accessible and versatile. We believe Nomic’s nELISA platform achieves exactly that.”
-Byron Hewett, former CEO of Somalogic and current board member at Nomic
“Nomic was founded to help scientific teams succeed in their mission to extend health spans. We’re excited to see our technology embraced by some of the most innovative R&D teams and to witness the nELISA platform advance critical drug discovery efforts. As we set out to greatly increase our biological footprint alongside unlocking several new applications, we are energized to partner with a distinguished group of investors who share our bold vision.”
-Milad Dagher, CEO and Co-founder of Nomic
